• Wenzhou Medical University wins two first prizes of Provincial Science and Technology Progress Award, ranking first among provincial universities by the total number of awards
  • On the morning of July 17, the Provincial Science and Technology Award Conference was solemnly held in the Provincial Great Hall of the People, and winners of the 2019 Provincial Science and Technology Award were announced. Ten scientific and technological achievements with WMU as the first completion unit won the awards. The project "theoretical innovation and new technology research and development of bacterial resistance detection of sepsis and stem cell diagnosis and treatment" led by Professor Pan Jingye and the project "molecular mechanism innovation and clinical transformation of fatty liver disease based on intestinal microecology" led by Professor Chen Yongping, both from the First Affiliated Hospital of WMU, won the first prizes of the Provincial Science and Technology Progress Award. In addition, one project was presented with the second prize and seven projects won the third prizes. WMU’s total number of awards ranked first among provincial universities. Vice President Jin Shengwei and award-winning representatives of WMU attended the meeting.

    Table of award-winning projects led by WMU

    Table of award-winning projects that WMU had participated in

    Introduction to the first prize projects

    Theoretical innovation and new technology research and development of bacterial resistance detection of sepsis and stem cell diagnosis and treatment

    Sepsis is a life-threatening organ dysfunction resulted from excessive inflammation caused by bacteria, viruses, and other pathogens invading the body. The incidence rate is about 5‰, and the mortality rate is as high as 25%. Studies have shown that 73% of sepsis are bacterial infections and 30-51% of sepsis cases involve microcirculation disorders. Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus account for about 50% of sepsis bacterial infections.

    Professor Pan Jingye’s team discovered novel loci of drug resistance gene in Klebsiella pneumoniae, the plasmid dissemination mechanism of drug resistance gene in Escherichia coli, and potential gene targets regulating capsule synthesis in Staphylococcus aureus. The team also further clarified the bacterial resistance, dissemination mechanism, and its clinical significance, providing a powerful foundation for rapid accurate diagnosis, isolation and anti-infection, thus reducing the incidence rate of sepsis. The team further revealed and clarified the new mechanism of bone mesenchymal stem cells treating septic organ dysfunction caused by infection. It was found that bone mesenchymal stem cells regulate sepsis inflammatory response and blood coagulation function through two important signal pathways of PAR1 and TLR2, 4/NF-κB, thereby improving sepsis organ dysfunction. The team gradually formed a theoretical system of perfusion activated microcirculation treatment that helped reduce the mortality of sepsis by inhibiting microthrombus, improving microcirculation, and restoring organ function.

    Authoritative journals such as Lancet Infectious Diseases (IF: 27.516), Stem Cells (IF: 6.022), Inflammation, and Shock highly praised the research results and cited them many times. The research results have been promoted and applied in 36 domestic hospitals. A total of 73 related papers have been published and 30 are included in SCI journals. In particular, the perfusion activated microcirculation treatment has been fully applied and verified in treating severe and critical COVID-19 cases in Wenzhou, with a success rate of 99.8%, which is much higher than the average level at home and abroad.

    Molecular mechanism innovation and clinical transformation of fatty liver disease based on intestinal microecology

    There are 320 million patients with fatty liver in our country, ranking first among chronic liver diseases. Every year, there are more than seven million cases of cirrhosis from fatty liver disease, and about 200,000 cases develop into liver cancer, which seriously endangers the health of our people. Previous studies on fatty liver mainly focused on insulin resistance, two or multiple hits, abnormal lipid metabolism, and susceptibility genes. The pathogenesis remains unclear.

    The team of Professor Chen Yongping discovered in clinical practice that the intestinal microecology of patients with fatty liver disease is obviously unbalanced, thus starting a new field of research on the regulation of the intestinal microecology of patients with fatty liver disease. After fifteen years of hard work, the team has carried out more than ten key projects funded by the government, such as the 12th and 13th five-year National Science and Technology Major Project, Nature Science Foundation of China, and Provincial Nature Science Foundation, cooperated with well-known scientific research institutions at home and abroad, and successfully established an animal model capable of accurately simulating the gut-liver axis disorder in fatty liver disease. They pioneered the use and innovation of new technologies and models of intestinal microecology regulation such as gene-modified stem cell transplantation, lactobacillus rhamnosus supernatant (short-chain fatty acid) infusion, and NSS fatty liver assessment model, and achieved breakthroughs and applications of key technologies such as early prediction, precise diagnosis and treatment, and targeted intervention. They also took the lead internationally in discovering the important protective effects of hypoxia inducible factor on intestinal barrier in the environment of intestinal flora imbalance, laying an important foundation for the development of diagnostic kits and targeted drugs for fatty liver disease. Their research has made world-leading achievements in China's prevention and treatment of fatty liver disease, which were highly praised by scholars of the international hepatology community, such as the world-famous gastroenterologist Wajahat Z. Mehal.

    The team has published more than 30 papers in influential hepatology journals including JOH, Clinical Gastroenterology and Hepatology, Liver International, and 11 papers in core journals published by CMA. The cumulative impact factor is more than 150 points. And these papers have been cited more than 200 times by top journals such as Nat Rev Gastroenterol Hepatol, JOH, GUT. The team has obtained three national authorized invention patents and two mobile phone applications copyrights. The internationally advanced achievements have been applied to seven million cases in more than 200 teaching hospitals and well-known hospitals, generating remarkable socioeconomic effects.

    It is reported that in 2019, a total of 709 candidate projects were recommended by the relevant departments, universities, institutions, and experts for the Provincial Science and Technology Award. After formal review, preliminary evaluation (online evaluation), professional evaluation, comprehensive appraisal, and public announcement, 297 scientific and technological innovation achievements won the 2019 Zhejiang Science and Technology Award, including two top scientific technology awards; 43 natural science awards (7 first prizes); 11 technological invention awards (3 first prizes); 240 science and technology progress awards (20 first prizes), and one award for international cooperation on science and technology.